Upcoming Challenges With Sequencing Frontline Treatment of CLL
Susan M. O’Brien, MD, discusses the challenges with the 3 oral agents approved in chronic lymphocytic leukemia.
Susan M. O’Brien, MD, associate director for clinical sciences, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, discusses the challenges with the 3 oral agents approved in chronic lymphocytic leukemia (CLL).
Ibrutinib (Imbruvica) is the only agent approved in the frontline setting currently, but venetoclax (Venclexta) is now being investigated in a randomized clinical trial with obinutuzumab (Gazyva), another novel anti-CD20 monoclonal antibody, O’Brien says. Based on that data, there may be more options for the frontline treatment of CLL, but it would make sequencing more complicated.
Novel BTK Degrader BGB-16673 Shows Activity in WM and CLL/SLL
December 10th 2024The novel Bruton tyrosine kinase degrader BGB-16673 shows promise in relapsed/refractory Waldenström macroglobulinemia previously exposed to BTK inhibitors, and in heavily pretreated patients with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma.
Read More
